Skip to content
Review

Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel.

Sep 2026 · Cancer Treatment Reviews · Vol 150, pp. 103216 · 0 citations · 38 references
Medicine

Abstract

Background

The management of metastatic castration-resistant prostate cancer (mCRPC) after progression on androgen receptor pathway inhibitors (ARPI) and docetaxel presents a critical therapeutic choice between cabazitaxel and [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). This review provides a comprehensive analysis of efficacy, toxicity, biomarkers, and treatment sequencing to guide clinical decision-making.

Methods

A critical review of the scientific literature was conducted, integrating data from randomized clinical trials, real-world evidence (RWE) studies, and preliminary data presented at major scientific conferences.

Findings

The head-to-head phase II TheraP trial demonstrated superior PSA response rates (66% vs 37%) and progression-free survival for [177Lu]Lu-PSMA-617 over cabazitaxel, without significant difference in overall survival (OS). In contrast, large RWE studies, including the ARON-3 study, consistently show a significant OS advantage for [177Lu]Lu-PSMA-617 (median OS 20.2 vs 14.8 months). [177Lu]Lu-PSMA-617 is associated with a more favorable safety profile, with a lower incidence of grade 3-4 adverse events (33% vs 53%) and superior patient-reported quality of life compared to cabazitaxel. PSMA-PET imaging serves as a key predictive biomarker, with a high SUVmean (≥10) identifying patients with the highest probability of response to PSMA-RLT. While both treatment sequences are clinically valid, a biological rationale may favor a PSMA-RLT -first approach. However, also cost-effectiveness analyses and local barriers play a role in the selection of the treatment pathway.

Conclusion

Available data suggest [177Lu]Lu-PSMA-617 as the preferred therapeutic option for the majority of patients with PSMA-positive mCRPC who progressed to ARPI and docetaxel. PSMA-RLT is preferred for most PSMA positive patients, with eligibility assessed individually rather than by rigid thresholds. Cabazitaxel remains a crucial treatment for patients with low PSMA expression, those ineligible for PSMA-RLT, or as an effective sequential therapy. Modern management of mCRPC demands a personalized, multidisciplinary approach to optimally balance survival gain with quality of life.

View source

Similar papers

Open access Oct 2026

Real-World Outcomes of 177Lu-PSMA-617 Radioligand Therapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer

Objective: Among recently developed treatment strategies for advanced prostate cancer, 177Lu-PSMA-617–based radioligand therapy has shown considerable clinical potential in patients with metastatic castration-resistant disease. However, predictors of treatment response and survival outcomes remain incompletely defined....

Ebru Karcı, T. Atasever, Tansel Çakır et al. · 0 citations
Review Open access Nov 2026

PSMA-Targeted Radioligand Therapy for Androgen Pathway Modulation-Resistant Prostate Cancer (APMR) in the Chemotherapy-Naïve Setting: A Narrative Review and Expert Commentary

This review examines the emerging evidence supporting the use of PSMA-targeted RLT in select patients with chemotherapy-naïve APMR, its potential role within current treatment pathways, and key considerations for patient selection, treatment sequencing, and the involvement of an experienced medical oncologist within a...

D. Jiang, K. Chi, U. Emmenegger et al. · 0 citations
Open access Sep 2026

Combinatorial Treatment Strategy of 177 Lu-PSMA-617 and Docetaxel Chemotherapy in Highly PSMA- and FDG-Avid (Pro-PET Score 3) Metastatic Castration-Resistant Prostate Cancer While Considering Pre-taxane PRLT

Abstract 177 Lu-PSMA-617 targeted radioligand therapy (RLT) received U.S. Food and Drug Administration approval in 2022 for metastatic castration-resistant prostate cancer (mCRPC) patients progressing after androgen receptor pathway inhibitors and taxane chemotherapy. Despite its efficacy, response rates vary, promptin...

Amal Paul, Keerti Sitani, Sandip Basu · 0 citations
Open access Oct 2026

Real-World PSA Response and Safety Outcomes of 177Lu-PSMA-617 in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Validation Study

Background/Objectives: 177Lu-PSMA-617 is an established standard-of-care treatment for eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Treatment schedules and follow-up in routine practice may differ from clinical trial protocols. Post-a...

Jin Hyeok Choi, Chang Gon Kim, K. T. Oh et al. · 0 citations
Review Open access Nov 2026

Implementation and Real-World Outcomes of [177Lu]Lu-PSMA-617 for Metastatic Androgen Pathway Modulation-Resistant Prostate Cancer: Following Public Reimbursement in Canada

[177Lu]Lu-PSMA-617 improves outcomes in patients with PSMA-positive metastatic Androgen Pathway Modulation-Resistant prostate cancer (mAPMR) previously treated with androgen deprivation therapy, androgen receptor pathway inhibitors and taxane chemotherapy; however, Canadian real-world data following public reimbursemen...

D. Jiang, P. Veit-Haibach, U. Metser et al. · 0 citations
Review Open access Oct 2026

[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing

Radioligand therapy delivers radiation to prostate cancer cells that express a protein called prostate-specific membrane antigen (PSMA) that delayed worsening on scans or death, but increased side effects, including severe adverse events and dry mouth.

C. Buonerba, G. Di Lorenzo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.